Loading...
•
Dec 31, 2021
Pulse Biosciences Q4 2021 Earnings Report
Announced financial results for the fourth quarter and full year of 2021.
Key Takeaways
Pulse Biosciences reported fourth quarter revenue of $844 thousand and full year revenue of $1.4 million. The company is focusing on increasing commercial clinic utilization and reducing emphasis on new system sales.
Implemented changes to commercial leadership, salesforce and strategy, to focus on increasing commercial clinic utilization.
Appointed two medical technology industry veterans to commercial leadership positions.
Initiated operating expense reduction programs, including workforce reductions, expected to lower costs by approximately 20% from the current run rate.
Completed the first three commercial sales of CellFX Systems, two in the fourth quarter of 2021 and one in the first quarter of 2022.
Pulse Biosciences
Pulse Biosciences
Forward Guidance
Pulse Biosciences is focused on increasing utilization at commercial clinics to develop CellFX reference centers for the benign lesion market under new commercial leadership, while also expanding the CellFX System’s indications for use in dermatology and beyond.
Positive Outlook
- Focusing on increasing commercial clinic utilization.
- Developing CellFX reference centers for the benign lesion market.
- Expanding the CellFX System’s indications for use in dermatology.
- Exploring applications for NPS technology beyond dermatology.
- Expecting an FDA meeting in Q2 2022 to discuss sebaceous hyperplasia 510(k).
Challenges Ahead
- Restructuring activities may be unexpectedly disruptive.
- Restructuring activities may be unexpectedly costly.
- Potential for unforeseen material delays in new product development programs.
- Potential for unforeseen material delays in commercialization efforts.
- Dependence on regulatory clearances for expansion of CellFX System's indications.